Nantahala Capital Management LLC recently announced the acquisition of new stake in Kintara Therapeutics Inc (NASDAQ:KTRA). This fresh investment now brings its stake to 0.67% valued currently at $7645.0. In addition, The Vanguard Group, Inc. raised its holdings by 12455.0 to 12455.0 shares.
With over 122.43 million Kintara Therapeutics Inc (KTRA) shares trading Friday and a closing price of $0.17 on the day, the dollar volume was approximately $20.81 million. The shares have shown a negative half year performance of -95.79% and its price on 12/29/23 lost nearly -12.12%. Currently, there are 3.39M common shares owned by the public and among those 3.31M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 60,163 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Kintara Therapeutics Inc are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Belfund SICAV – Belinvest Equity. Vanguard Extended Market Index Fu owns 12455.0 shares of the company’s stock, all valued at over $4210.0. Belfund SICAV – Belinvest Equity now owns shares totaling to 0.16% of the shares outstanding.
Shares of Kintara Therapeutics Inc (NASDAQ: KTRA) opened at $0.289, up $0.1 from a prior closing price of $0.19. However, the script later moved the day high at 0.2948, down -12.12%. The company’s stock has a 5-day price change of -7.78% and -95.80% over the past three months. KTRA shares are trading -97.54% year to date (YTD), with the 12-month market performance down to -97.77% lower. It has a 12-month low price of $0.16 and touched a high of $9.00 over the same period. KTRA has an average intraday trading volume of 985.41K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -24.08%, -82.96%, and -94.42% respectively.
Institutional ownership of Kintara Therapeutics Inc (NASDAQ: KTRA) shares accounts for 2.30% of the company’s 3.39M shares outstanding. Mutual fund holders own 1.36%, while other institutional holders and individual stakeholders account for 2.08% and 0.93% respectively.
It has a market capitalization of $0.57M and a beta (3y monthly) value of 0.67. The earnings-per-share (ttm) stands at -$7.84. Price movements for the stock have been influenced by the stock’s volatility, which stands at 24.91% over the week and 19.08% over the month.
Analysts forecast that Kintara Therapeutics Inc (KTRA) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and -$0.83 for 2025. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$3.5 a year ago. Earnings per share for the fiscal year are expected to increase by 88.67%, and 21.43% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Kintara Therapeutics Inc (KTRA) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 2 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
